Mosaic ImmunoEngineering (OTCMKTS:CPMV – Get Free Report) posted its earnings results on Wednesday. The company reported ($0.02) earnings per share for the quarter, Zacks reports.
Mosaic ImmunoEngineering Price Performance
OTCMKTS:CPMV remained flat at $0.69 during trading hours on Wednesday. Mosaic ImmunoEngineering has a one year low of $0.25 and a one year high of $1.05. The stock has a market cap of $5.03 million, a PE ratio of -6.95 and a beta of -0.68. The stock has a fifty day moving average of $0.66 and a 200-day moving average of $0.58.
Mosaic ImmunoEngineering Company Profile
Mosaic ImmunoEngineering (OTCMKTS:CPMV) is a development-stage biotechnology company focused on advancing immunotherapies and vaccine candidates through its proprietary nanoparticle platform. The company leverages virus-like particles derived from the cowpea mosaic virus (CPMV) to serve as both antigen carriers and immune stimulators, aiming to enhance the magnitude and durability of immune responses. By engineering these plant-based VLPs to display target antigens or adjuvant properties, Mosaic ImmunoEngineering seeks to create differentiated candidates for oncology indications and infectious disease prevention.
Operating out of the United States, Mosaic ImmunoEngineering is currently in preclinical stages of development.
Featured Stories
- Five stocks we like better than Mosaic ImmunoEngineering
- The Great Cloud Divide: How AI Is Reshuffling the Software Deck
- Eagle Materials: A Dividend-Paying Brick & Mortar AI Play
- Analog Devices Provides Much-Needed Pullback: How Low Can It Go?
- Arhaus Stock Drops to 52-Week Low After Q1 Earnings
Receive News & Ratings for Mosaic ImmunoEngineering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mosaic ImmunoEngineering and related companies with MarketBeat.com's FREE daily email newsletter.
